Characterizing Methamphetamine Withdrawal in Recently Abstinent Methamphetamine Users: A Pilot Study
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00653263|
Recruitment Status : Completed
First Posted : April 4, 2008
Results First Posted : March 9, 2010
Last Update Posted : March 9, 2010
|Condition or disease|
|Methamphetamine Dependence Methamphetamine Withdrawal|
|Study Type :||Observational|
|Actual Enrollment :||8 participants|
|Official Title:||Characterizing Methamphetamine Withdrawal in Recently Abstinent Methamphetamine Users: A Pilot Study|
|Study Start Date :||August 2006|
|Actual Primary Completion Date :||August 2008|
|Actual Study Completion Date :||August 2008|
Methamphetamine dependent participants admitted to Recovery Centers of Arkansas
- Methamphetamine Selective Severity Assessment (MSSA) [ Time Frame: Baseline through week 4 ]Methamphetamine Selective Severity Assessment (MSSA) is an 18 item questionnaire assessing withdrawal symptoms with each question measured on a scale from 0(best score)-7(worst score) for a range in scores from 0(best score)-126(worst score). Higher scores indicate more severe withdrawal symptoms.
- Methamphetamine Withdrawal Assessment (MAWA) [ Time Frame: Baseline through week 4 ]The Methamphetamine Withdrawal Assessment (MAWA) is a 13 item questionnaire which measures symptoms of methamphetamine withdrawal on a scale from 0(best score)-4(worst score). The total score ranges from 0(best score)-52(worst score).
- Hamilton Depression Rating Scale (HAM-D) Rating Score [ Time Frame: 4 weeks ]Hamilton Depression rating scale (HAM-D)is a scale that covers 21 symptoms with a total score of 0(best score)-62 (worst score) and a cutoff for moderate depression of 15 or above.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00653263
|United States, Arkansas|
|University of Arkansas for Medical Sciences|
|Little Rock, Arkansas, United States, 72205|
|Principal Investigator:||Michael J Mancino, M.D.||University of Arkansas|
|Study Chair:||Alison Oliveto, PhD||University of Arkansas|